Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 157

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 157
---
ation became a wholly owned subsidiary of the Company. See Note 1b. In consideration for the contribution 
 of all of their shareholdings in LipoVation to the Company, the Company issued to the former LipoVation shareholders an aggregate of 23,171,642 
 restricted shares of the Company’s common stock, representing 40% of the outstanding shares of the Company immediately following                
 the closing.                                                                                                                                    |

| c. | On November 11, 2024, following discussions with the management of the Company, the Board has determined                                      
 that it is advisable and in the best interests of the Company and its stockholders to further amend the Plan, as amended (“Amendment          
 #2”), to reduce the maximum number of shares reserved for issuance under the Plan from 20,000,000 shares of Common Stock to 10,000,000        
 shares of Common Stock. Amendment No. 2 became effective on the date of the approval by the Board of Directors, but it is subject to approval 
 by the Company’s shareholders within 12 months, pursuant to section 422(b)(1) of the Internal Revenue Code.                                   |

| e. | On December 31, 2024, the Board approved a grant under the Company’s Global Share Incentive Plan                                            
 (2021) to an employee of LipoVation of 740,000 stock options at an exercise price of $0.30 per share. Of the options granted, options       
 for 560,000 shares were fully vested upon grant and the remaining 180,000 options are to be vest on April 10, 2025. The options exercisable 
 within eight years from grant date                                                                                                          |

<div align='center'>F-48

[RESALE PROSPECTUS ALTERNATE PAGE]</div>

The information in this Prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.

| PRELIMINARY 
 PROSPECTUS  | SUBJECT       
 TO COMPLETION | DATED            
 FEBRUARY__, 2025 |

<div align='center'>REVIUM RX.

Up to 37,625,790 Shares of Common Stock</div>

This Resale Prospectus relates to the resale, from time